Kolte-Patil Developers Zukünftiges Wachstum
Future Kriterienprüfungen 6/6
Kolte-Patil Developers wird ein jährliches Gewinn- und Umsatzwachstum von 78.3% bzw. 21.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 75.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 24.2% betragen.
Wichtige Informationen
85.2%
Wachstumsrate der Gewinne
89.0%
EPS-Wachstumsrate
| Real Estate Gewinnwachstum | 27.7% |
| Wachstumsrate der Einnahmen | 28.4% |
| Zukünftige Eigenkapitalrendite | 20.5% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 12 Aug 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Kolte-Patil Developers (NSE:KOLTEPATIL) Is Due To Pay A Dividend Of ₹4.00
Jul 28
New Forecasts: Here's What Analysts Think The Future Holds For Kolte-Patil Developers Limited (NSE:KOLTEPATIL)
May 30Kolte-Patil Developers Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 29Optimistic Investors Push Kolte-Patil Developers Limited (NSE:KOLTEPATIL) Shares Up 34% But Growth Is Lacking
Apr 13We Ran A Stock Scan For Earnings Growth And Kolte-Patil Developers (NSE:KOLTEPATIL) Passed With Ease
Apr 11Earnings Tell The Story For Kolte-Patil Developers Limited (NSE:KOLTEPATIL)
Jan 05Is Kolte-Patil Developers (NSE:KOLTEPATIL) Using Too Much Debt?
Nov 21Here's Why Kolte-Patil Developers (NSE:KOLTEPATIL) Has Caught The Eye Of Investors
Nov 02These 4 Measures Indicate That Kolte-Patil Developers (NSE:KOLTEPATIL) Is Using Debt Reasonably Well
Jun 01These 4 Measures Indicate That Kolte-Patil Developers (NSE:KOLTEPATIL) Is Using Debt Extensively
Jun 01How Should Investors Feel About Kolte-Patil Developers' (NSE:KOLTEPATIL) CEO Remuneration?
Feb 28What Percentage Of Kolte-Patil Developers Limited (NSE:KOLTEPATIL) Shares Do Insiders Own?
Feb 07Have Insiders Been Buying Kolte-Patil Developers Limited (NSE:KOLTEPATIL) Shares?
Jan 17The Kolte-Patil Developers (NSE:KOLTEPATIL) Share Price Is Up 55% And Shareholders Are Holding On
Dec 27
Does Kolte-Patil Developers (NSE:KOLTEPATIL) Have A Healthy Balance Sheet?
Nov 30Here's What We Think About Kolte-Patil Developers' (NSE:KOLTEPATIL) CEO Pay
Nov 04Trade Alert: The Independent Non-Executive Director Of Kolte-Patil Developers Limited (NSE:KOLTEPATIL), Umesh Joshi, Has Just Spent ₹1.6m Buying A Few More Shares
Sep 30What Type Of Returns Would Kolte-Patil Developers'(NSE:KOLTEPATIL) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Sep 17Are Kolte-Patil Developers's (NSE:KOLTEPATIL) Statutory Earnings A Good Guide To Its Underlying Profitability?
Aug 18How Does Kolte-Patil Developers Limited (NSE:KOLTEPATIL) Fare As A Dividend Stock?
Jul 31Is Kolte-Patil Developers (NSE:KOLTEPATIL) A Risky Investment?
Jul 13Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2027 | 24,865 | 2,598 | N/A | N/A | 2 |
| 3/31/2026 | 25,029 | 2,323 | 164 | N/A | 5 |
| 3/31/2025 | 18,937 | 871 | -251 | N/A | 5 |
| 6/30/2024 | 11,411 | -1,091 | N/A | N/A | N/A |
| 3/31/2024 | 13,715 | -693 | -1,541 | -1,110 | N/A |
| 12/31/2023 | 16,420 | 736 | N/A | N/A | N/A |
| 9/30/2023 | 19,343 | 1,107 | -34 | 293 | N/A |
| 6/30/2023 | 18,595 | 1,272 | N/A | N/A | N/A |
| 3/31/2023 | 14,884 | 1,041 | 1,792 | 1,977 | N/A |
| 12/31/2022 | 10,893 | 124 | N/A | N/A | N/A |
| 9/30/2022 | 9,595 | 447 | 1,541 | 1,732 | N/A |
| 6/30/2022 | 11,312 | 711 | N/A | N/A | N/A |
| 3/31/2022 | 11,175 | 794 | 3,429 | 3,549 | N/A |
| 12/31/2021 | 10,494 | 734 | N/A | N/A | N/A |
| 9/30/2021 | 9,956 | 905 | 4,123 | 4,179 | N/A |
| 6/30/2021 | 7,491 | 510 | N/A | N/A | N/A |
| 3/31/2021 | 6,999 | -55 | 3,180 | 3,238 | N/A |
| 12/31/2020 | 6,254 | -428 | N/A | N/A | N/A |
| 9/30/2020 | 5,653 | -784 | 2,724 | 2,818 | N/A |
| 6/30/2020 | 6,846 | -705 | N/A | N/A | N/A |
| 3/31/2020 | 11,375 | 724 | 3,245 | 3,349 | N/A |
| 12/31/2019 | 11,077 | 1,277 | N/A | N/A | N/A |
| 9/30/2019 | 10,498 | 1,292 | 1,029 | 1,080 | N/A |
| 6/30/2019 | 10,644 | 1,534 | N/A | N/A | N/A |
| 3/31/2019 | 8,704 | 754 | 639 | 674 | N/A |
| 12/31/2018 | 11,539 | 759 | N/A | N/A | N/A |
| 9/30/2018 | 13,706 | 1,168 | N/A | N/A | N/A |
| 6/30/2018 | 15,471 | 1,362 | N/A | N/A | N/A |
| 3/31/2018 | 14,057 | 1,215 | N/A | 2,298 | N/A |
| 12/31/2017 | 12,565 | 1,124 | N/A | N/A | N/A |
| 9/30/2017 | 11,953 | 1,024 | N/A | N/A | N/A |
| 6/30/2017 | 10,324 | 921 | N/A | N/A | N/A |
| 3/31/2017 | 9,638 | 872 | N/A | 1,426 | N/A |
| 12/31/2016 | 7,690 | 745 | N/A | N/A | N/A |
| 9/30/2016 | 7,211 | 702 | N/A | N/A | N/A |
| 6/30/2016 | 6,761 | 635 | N/A | N/A | N/A |
| 3/31/2016 | 7,538 | 589 | N/A | 364 | N/A |
| 12/31/2015 | 6,580 | 546 | N/A | N/A | N/A |
| 9/30/2015 | 7,134 | 611 | N/A | N/A | N/A |
| 6/30/2015 | 7,109 | 606 | N/A | N/A | N/A |
| 3/31/2015 | 6,966 | 653 | N/A | 344 | N/A |
| 12/31/2014 | 7,246 | 647 | N/A | N/A | N/A |
| 9/30/2014 | 6,912 | 653 | N/A | N/A | N/A |
| 6/30/2014 | 6,975 | 849 | N/A | N/A | N/A |
| 3/31/2014 | 7,642 | 920 | N/A | -1,170 | N/A |
| 12/31/2013 | 8,045 | 1,241 | N/A | N/A | N/A |
| 9/30/2013 | 8,413 | 1,342 | N/A | N/A | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: KOLTEPATIL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (6.7%).
Ertrag vs. Markt: KOLTEPATIL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: KOLTEPATIL wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: KOLTEPATILDie Einnahmen des Unternehmens (21.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (9.6% pro Jahr).
Hohe Wachstumseinnahmen: KOLTEPATILDie Einnahmen des Unternehmens (25.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: KOLTEPATILDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (24.2%)